Literature DB >> 21964701

Progressive leukoencephalopathy with intracranial calcification, congenital deafness, and developmental deterioration.

Ichiro Kuki1, Hisashi Kawawaki, Shin Okazaki, Shihoko Kimura-Ohba, Tomoaki Nakano, Hiroko Fukushima, Takeshi Inoue, Kiyotaka Tomiwa, Masayuki Itoh.   

Abstract

We report on a 12-year-old male with a unique cerebral white matter disease. His initial symptoms were congenital hearing loss and multiple intracranial calcifications on head CT. He developed severe intellectual disability and epilepsy. MRI showed signal abnormalities in the posterior limbs of the internal capsules, thalami, and cerebral white matter. The abnormalities were progressive over time. The neuropathology revealed diffuse and severe disruption of myelin and axons of the cerebral white matter and cerebrospinal tracts. We performed various metabolic examinations, detailed pathological investigations and genetic analyses, but could not identify the cause. To our knowledge his clinical course has not been described in the literature.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21964701     DOI: 10.1002/ajmg.a.34256

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  1 in total

1.  Bi-allelic KARS1 pathogenic variants affecting functions of cytosolic and mitochondrial isoforms are associated with a progressive and multisystem disease.

Authors:  Gerarda Cappuccio; Camilla Ceccatelli Berti; Enrico Baruffini; Jennifer Sullivan; Vandana Shashi; Tamison Jewett; Tara Stamper; Silvia Maitz; Francesco Canonico; Anya Revah-Politi; Gabriel S Kupchik; Kwame Anyane-Yeboa; Vimla Aggarwal; Andreas Benneche; Eirik Bratland; Siren Berland; Felice D'Arco; Cesar A Alves; Adeline Vanderver; Daniela Longo; Enrico Bertini; Annalaura Torella; Vincenzo Nigro; Alessandra D'Amico; Marjo S van der Knaap; Paola Goffrini; Nicola Brunetti-Pierri
Journal:  Hum Mutat       Date:  2021-05-11       Impact factor: 4.700

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.